Sep 23,2020 02:05 PM
The Nifty Pharma index has touched the day's low of 11,627.50 with selling bias recorded in all listed stocks.
Nifty reclaims 11,550-mark; Pharma stocks rally Sep 18,2020
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||503.75||41.10||122,474.05||531.95||0.78||2,878.64||101.68|
|Dr Reddys Laboratories Ltd||5,129.20||25.76||86,041.95||950.20||0.48||3,244.40||919.82|
|Divis Laboratories Ltd||3,158.55||53.74||85,855.19||492.25||0.49||1,709.96||275.61|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilar... More
Reports by dr-reddys-laboratories-ltd
Sep 23, 2020
Dr. Reddy’s Laboratories (DRL), India’s second-largest pharma company, is expected to see earnings recovery led by cost rationalization and new product approvals; recommendation based on 18x FY21E...More
Sep 23, 2020 03:09 PM
The company’s consolidated revenue stood at Rs3,858cr, up 3.3% yoy but down 4.3% qoq.
30 Jul 2020
17 Jun 2020
AGM 30/07/2020Notice of 36th Annual General Meeting (AGM) and Annual Report 2019-20(As Per BSE Annou... More
29 Jul 2020
27 Jun 2020
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Compan... More
20 May 2020
13 Jul 2020
Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meetin... More